The association of serum antiphospholipid antibodies and dilute Russell's viper venom times

Journal of Clinical Pathology

Volumn 67, Issue 5, 2014, Pages 441-444

  Froom, Paul ^a   Saffuri Elias, Enas ^a   Rozenberg, Orit ^a   Barak, Mira ^a  

^a CLALIT HEALTH SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; IMMUNOGLOBULIN G ANTIBODY; PHOSPHOLIPID ANTIBODY; VIPER VENOM;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DABOIA RUSSELLII; DILUTE RUSSELL VIPER VENOM TIME; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN G ANTIPHOSPHOLIPID ANTIBODY TEST; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE;

ANTIBODIES; ANTIPHOSPHOLIPID; HAEMATOLOGY; HAEMOPHILIA; LABORATORY TESTS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; BLOOD COAGULATION; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; THROMBOEMBOLISM; UP-REGULATION; YOUNG ADULT;

EID: 84901714584     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201830     Document Type: Article

References (15)

1. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737-40.
2. Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012;64:1-10.
3. Pengo V. A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008;6:1048-9.
4. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147-52.
5. Forastiero R, Marinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin and risk of thrombosis. J Thromb Haemost 2005;3:1231-8.
6. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011;118:4714-18.
7. Pengo V, Denas G, Banzato A, et al. Interpretation of laboratory data and need for reference laboratories. Lupus 2012;21:732-3.
8. Froom P, Barak M. Lupus anticoagulant testing: analyzing fresh samples after a single centrifugation and after a 6-8 h delay. Clin Chem Lab Med 2011;50:367-70.
9. Froom P, Barak M. Testing for lupus anticoagulants - fresh or frozen? Clin Chem Lab Med 2012;50:1607-9.
10. Keeling D, Mackie I, Moore GW, et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47-58.
11. Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol 2009;83:1-16.
12. Gerbutavicius R, Fareed J, Messmore HL Jr, et al. Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited. Clin Appl Thromb Hemost 2002;8:115-24.
13. Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem 1971;17:275-84.
14. Gardiner C, MacKie IJ, Malia RG, et al. The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. Br J Haematol 2000;111:1230-5.
15. Roubey RA. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus 2010;19:440-5.